40+ projects, 30+ partnerships: PSA’s projects make a bigger impact than ever before
6 November 2025
The Pharmaceutical Society of Australia (PSA) released its 2025 Strategic Projects Impact Report today, showcasing PSA’s leadership in advancing pharmacist practice and promoting medicines safety nationally. The report highlights how PSA drives the safe use of medicines forward, through projects in palliative care, mental health, and vaping reform that demonstrate collaborative, evidence-based initiatives.
In 2025, the PSA’s Projects team delivered more than 40 initiatives in collaboration with over 30 partners, cementing PSA’s role as the national peak body driving the Quality Use of Medicines (QUM) agenda.
The PSA’s commitment to supporting pharmacists through change is demonstrated in the report with key education projects including:
The National Palliative Care Project (2023-2026): The PSA is committed to improving palliative care by building pharmacist capability, integrating pharmacist roles into interdisciplinary care teams, and ensuring patients and carers receive safe, compassionate, and person-centred support wherever they are. In May 2025, PSA launched its ASPIRE Palliative Care Foundation Training Program for pharmacists. Within six weeks, more than 1000 pharmacists were enrolled.
Mental Health First Aid (MHFA) training: The PSA’s MHFA training aims to address the gaps in mental health literacy and confidence, aspiring to “Recognise, Respond, and Support”. In 2025, 654 pharmacists and pharmacy staff had completed PSA’s MHFA course.
Vaping reform: The PSA rolled out a series of webinars and modules on navigating vaping reform throughout 2025, as education is essential for the consistency and confidence of pharmacists. With over 1000 registrations for the first webinar, the highest in PSA’s history, more than 2500 pharmacists have participated in vaping education and training.
National PSA President, Associate Professor Fei Sim FPs, said translating policy into practice and equipping pharmacists to lead innovation meant PSA continued to build a future where pharmacists were fully enabled to provide person-centred care across all areas of practice.
“The Impact Report demonstrates PSA’s unwavering commitment to excellence, collaboration, and measurable national impact in improving the quality use of medicines,” she said.
“Pharmacists play a vital role in supporting symptom management, medicines optimisation, and continuity of care at the end of life, yet their expertise has not been systematically embedded across community and primary care settings.
“In addition to driving innovation through projects and pilots, we are committed to supporting the pharmacy workforce with education, training, and practice support regardless of policy decisions. This ensures pharmacists and pharmacy support staff have the confidence to meet regulatory requirements, ensuring clarity, consistency, and alignment with the needs of both consumers and our health system.”
The PSA 2025 Impact Report is available for download here
Media contact: Leah Jacobsen M: 0480 099 798 E: leah.jacobsen@psa.org.au
The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.